Prevention of influenza disease caused by the 2 influenza A virus subtypes & the 2 influenza B virus types contained in the vaccine for active immunisation of adults, including pregnant women, & childn ≥6 mth; & passive protection of infant from birth to <6 mth of age following vaccination of pregnant women.
IM or SCAdult 1 dose of 0.5 mL. Childn 6 mth-17 yr 1 dose of 0.5 mL, <9 yr who have not previously been vaccinated A 2nd dose of 0.5 mL should be given after an interval of at least 4 wk. Passive protection 1 dose of 0.5 mL to pregnant women.
Hypersensitivity to influenza vaccine or to any component that may be present as traces eg, eggs (ovalbumin, chicken proteins), neomycin, formaldehyde & octoxinol-9. Postpone vaccination in case of moderate or severe febrile disease or acute disease.
Not to be administered intravascularly. Anaphylactic reaction following administration. Patients w/ thrombocytopaenia or bleeding disorder. Syncope (fainting). May not protect all vaccinees. Ab response in patients w/ endogenous or iatrogenic immunosuppression may be insufficient. Regarding passive protection, not all infants <6 mth born to women vaccinated during pregnancy will be protected.
Sign Out
